Takeda Expected to Report Return to Profit for Second Quarter

Dow Jones10-28
 
 

Takeda Pharmaceutical is scheduled to report second-quarter results on Thursday. Here's what you need to know:

 

NET PROFIT FORECAST: Takeda is expected to post net profit of 67.8 billion yen, equivalent to $429.2 million, for the three months ended September, according to a poll of analysts by Visible Alpha. The drugmaker booked a net loss of Y11.8 billion in the year-earlier period.

 

REVENUE FORECAST: Revenue is estimated to have risen 3.6% to Y1.153 trillion, according to the Visible Alpha poll.

 

The stock has risen 30% year to date, compared with a 27% gain in the Nikkei Stock Average.

 

WHAT TO WATCH:

--For the fiscal year ending March 2027, the company has projected a 3.0% rise in revenue to Y4.640 trillion and net profit of Y166.00 billion, compared with a net loss the previous year. Investors will be focusing on changes to annual guidance as well as any impact on its operations from higher energy prices and interest rates.

--First-quarter sales of ulcerative colitis drug Entyvio climbed 15% to Y268.3 billion, while sales of plasma-derived products rose 8.8% to Y283.9 billion. Investors will be closely watching for sales momentum of key products.

--The company's operating profit margin was 16.5% in its first quarter, compared with 16.7% in the year-earlier period. Investors will be paying attention to margin trends as businesses are dealing with relatively high inflation in many parts of the world.

 
 

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment